| The molecular portraits of breast tumors are conserved across microarray platforms Z Hu, C Fan, DS Oh, JS Marron, X He, BF Qaqish, C Livasy, LA Carey, ... BMC genomics 7, 1-12, 2006 | 1873 | 2006 |
| Phenotypic evaluation of the basal-like subtype of invasive breast carcinoma CA Livasy, G Karaca, R Nanda, MS Tretiakova, OI Olopade, DT Moore, ... Modern pathology 19 (2), 264-271, 2006 | 1528 | 2006 |
| Pembrolizumab in patients with advanced triple-negative breast cancer: phase Ib KEYNOTE-012 study R Nanda, LQM Chow, EC Dees, R Berger, S Gupta, R Geva, L Pusztai, ... Journal of Clinical oncology 34 (21), 2460, 2016 | 1522 | 2016 |
| Pembrolizumab monotherapy for previously treated metastatic triple-negative breast cancer: cohort A of the phase II KEYNOTE-086 study S Adams, P Schmid, HS Rugo, EP Winer, D Loirat, A Awada, DW Cescon, ... Annals of Oncology 30 (3), 397-404, 2019 | 702 | 2019 |
| Long-term clinical outcomes and biomarker analyses of atezolizumab therapy for patients with metastatic triple-negative breast cancer: a phase 1 study LA Emens, C Cruz, JP Eder, F Braiteh, C Chung, SM Tolaney, I Kuter, ... JAMA oncology 5 (1), 74-82, 2019 | 688 | 2019 |
| Adaptive randomization of veliparib–carboplatin treatment in breast cancer HS Rugo, OI Olopade, A DeMichele, C Yau, LJ van’t Veer, MB Buxton, ... New England Journal of Medicine 375 (1), 23-34, 2016 | 584 | 2016 |
| Pembrolizumab monotherapy for previously untreated, PD-L1-positive, metastatic triple-negative breast cancer: cohort B of the phase II KEYNOTE-086 study S Adams, S Loi, D Toppmeyer, DW Cescon, M De Laurentiis, R Nanda, ... Annals of Oncology 30 (3), 405-411, 2019 | 537 | 2019 |
| Effect of pembrolizumab plus neoadjuvant chemotherapy on pathologic complete response in women with early-stage breast cancer: an analysis of the ongoing phase 2 adaptively … R Nanda, MC Liu, C Yau, R Shatsky, L Pusztai, A Wallace, AJ Chien, ... JAMA oncology 6 (5), 676-684, 2020 | 533 | 2020 |
| Population differences in breast cancer: survey in indigenous African women reveals over-representation of triple-negative breast cancer D Huo, F Ikpatt, A Khramtsov, JM Dangou, R Nanda, J Dignam, B Zhang, ... Journal of clinical oncology 27 (27), 4515, 2009 | 477 | 2009 |
| Enzalutamide for the treatment of androgen receptor–expressing triple-negative breast cancer TA Traina, K Miller, DA Yardley, J Eakle, LS Schwartzberg, ... Journal of clinical oncology 36 (9), 884, 2018 | 476 | 2018 |
| Adaptive randomization of neratinib in early breast cancer JW Park, MC Liu, D Yee, C Yau, LJ van’t Veer, WF Symmans, M Paoloni, ... New England Journal of Medicine 375 (1), 11-22, 2016 | 358 | 2016 |
| TBCRC 048: phase II study of olaparib for metastatic breast cancer and mutations in homologous recombination-related genes NM Tung, ME Robson, S Ventz, CA Santa-Maria, R Nanda, PK Marcom, ... Journal of Clinical Oncology 38 (36), 4274-4282, 2020 | 317 | 2020 |
| A genome-wide screen for promoter methylation in lung cancer identifies novel methylation markers for multiple malignancies DS Shames, L Girard, B Gao, M Sato, CM Lewis, N Shivapurkar, A Jiang, ... PLoS medicine 3 (12), e486, 2006 | 302 | 2006 |
| Advances in breast cancer: pathways to personalized medicine OI Olopade, TA Grushko, R Nanda, D Huo Clinical Cancer Research 14 (24), 7988-7999, 2008 | 287 | 2008 |
| Genetic testing in an ethnically diverse cohort of high-risk women: a comparative analysis of BRCA1 and BRCA2 mutations in American families of European and African ancestry R Nanda, LP Schumm, S Cummings, JD Fackenthal, L Sveen, ... Jama 294 (15), 1925-1933, 2005 | 285 | 2005 |
| Multicenter phase II study of neoadjuvant lapatinib and trastuzumab with hormonal therapy and without chemotherapy in patients with human epidermal growth factor receptor 2 … MF Rimawi, IA Mayer, A Forero, R Nanda, MP Goetz, AA Rodriguez, ... Journal of clinical oncology 31 (14), 1726, 2013 | 278 | 2013 |
| The role of tumor-associated macrophages in breast cancer progression E Obeid, R Nanda, YX Fu, OI Olopade International journal of oncology 43 (1), 5-12, 2013 | 251 | 2013 |
| Pembrolizumab plus standard neoadjuvant therapy for high-risk breast cancer (BC): results from I-SPY 2. R Nanda, MC Liu, C Yau, S Asare, N Hylton, LV Veer, J Perlmutter, ... Journal of Clinical Oncology 35 (15_suppl), 506-506, 2017 | 247 | 2017 |
| Magnetic resonance imaging as a predictor of pathologic response in patients treated with neoadjuvant systemic treatment for operable breast cancer: Translational Breast Cancer … JF De Los Santos, A Cantor, KD Amos, A Forero, M Golshan, JK Horton, ... Cancer 119 (10), 1776-1783, 2013 | 225 | 2013 |
| BRCA1 promoter methylation in sporadic breast cancer is associated with reduced BRCA1 copy number and chromosome 17 aneusomy M Wei, TA Grushko, J Dignam, F Hagos, R Nanda, L Sveen, J Xu, ... Cancer research 65 (23), 10692-10699, 2005 | 222 | 2005 |
